None listed
Conditions
Brief summary
Chronic obstructive pulmonary disease (COPD) is a debilitating condition that results from inflammation of the airways. This inflammation impairs lung function and thus reduces an individuals’ ability to undertake physical activities, including activities of daily living. Long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) have been shown in a number of studies to elicit anti-inflammatory effects. People with COPD will be supplemented with either LCn-3PUFA or placebo; effects on inflammation, lung and physical function will be assessed at four months. It is anticipated that supplementation with LCn-3PUFA will reduce inflammation, and improve physical function (exercise capacity), which will collectively improve health related quality of life
Interventions
A double-blind, randomised, placebo-controlled intervention trial designed to evaluate whether fish oil supplementation (6 x 1g/day for 4 months) can reduce inflammation and mediate improvements in functional exercise capacity in patients with chronic obstructive pulmonary disorder (COPD). Forty volunteers will be recruited through public advertisements and from a patient database maintained by the Department of Respiratory Medicine in the Southern Adelaide Health Network. They will have a clini
A double-blind, randomised, placebo-controlled intervention trial designed to evaluate whether fish oil supplementation (6 x 1g/day for 4 months) can reduce inflammation and mediate improvements in functional exercise capacity in patients with chronic obstructive pulmonary disorder (COPD). Forty volunteers will be recruited through public advertisements and from a patient database maintained by the Department of Respiratory Medicine in the Southern Adelaide Health Network. They will have a clinical and spirometric diagnosis of COPD. Prior to the commencement of the study volunteers will complete a series of questionnaires and tests designed to assess lung and physical function, diet history and quality of life. Blood samples will be collected and assayed for dietary and inflammatory biomarkers. Volunteers will be randomised to to one of two groups: 1. Fish oil - 6 x 1g capsules (approximately 3.6g/day long chain omega-3 polyunsaturated fatty acids) 2. Placebo - 6 x 1g capsules (corn oil) Functional and biochemical assessments will be repeated at four months following commencement. A symptom diary will be used to assess frequency and severity of exacerbation symptoms during the study. Upon completion of the study participant experience and perspectives will be gathered using a structured telephone interview.
Sponsors
Dr. Alison Hill
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Aged between 18-80 years 2. Have a clinical and spirometric diagnosis of COPD (forced expiratory volume (FEV1) <80% of predicted and best recorded ratio of FEV1 to forced vital capacity (FEV1/FVC) <0.70) 3.Stable dose of medication for 28 days prior to entering the study
Exclusion criteria
1. Use of fish oil (>1g/day for 3 months); 2. Self-reported presence of unstable co morbidities (right heart failure, sleep disorders, metabolic pathologies); 3. Current smoker; 4. GOLD stage IV COPD (due to the high likelihood of irreversible airways remodelling); 5. a-antitrypsin deficiency; 6. Cachexia (unintentional weight loss exceeding 5% within the previous 3-12 months) or body mass index (BMI) < 18.5kg/m2; 7. Morbid obesity (BMI >40kg/m2); 8. A mini mental assessment score of <23 to ensure that participants are cognitively able to complete assessments; 9. Clinically unstable COPD; 10. Use of steroid or antibiotic medication for 28 days prior to baseline visit; 11. Patients with respiratory conditions not related to airflow limitation (e.g. primary pulmonary hypertension, post-lobectomy for lung cancer, or pulmonary fibrosis); 12. Participation in a comprehensive pulmonary rehabilitation program in the previous 2 years; 13. Intending to undertake a pulmonary rehabilitation program in the next 6 months. 14. Use of Warfarin medication
Outcome results
None listed